Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Glioblastoma is the most common primary malignant brain tumor in adults and associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune responses and survival following neoadjuvant and/or adjuvan...

Descripción completa

Detalles Bibliográficos
Autores principales: Cloughesy, Timothy F., Mochizuki, Aaron Y., Orpilla, Joey R., Hugo, Willy, Lee, Alexander H., Davidson, Tom B., Wang, Anthony C., Ellingson, Benjamin M., Rytlewski, Julie A., Sanders, Catherine M., Kawaguchi, Eric S., Du, Lin, Li, Gang, Yong, William H., Gaffey, Sarah C., Cohen, Adam L., Mellinghoff, Ingo K., Lee, Eudocia Q., Reardon, David A., O’Brien, Barbara J., Butowski, Nicholas A., Nghiemphu, Phioanh L., Clarke, Jennifer L., Arrillaga-Romany, Isabel C., Colman, Howard, Kaley, Thomas J., de Groot, John F., Liau, Linda M., Wen, Patrick Y., Prins, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408961/
https://www.ncbi.nlm.nih.gov/pubmed/30742122
http://dx.doi.org/10.1038/s41591-018-0337-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408961/
https://www.ncbi.nlm.nih.gov/pubmed/30742122
http://dx.doi.org/10.1038/s41591-018-0337-7

Ejemplares similares